Payload Information
General Information of This Payload
| Payload ID | PAY0WBGAF |
|||||
|---|---|---|---|---|---|---|
| Name | IG-L-48 Payload |
|||||
| Synonyms |
IG-L-48 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C22H18ClF2N3O4 |
|||||
| Isosmiles | O=C(N1)CCC(N2CC3=CC(CNC(C(F)(F)C4=CC=C(Cl)C=C4)=O)=CC=C3C2=O)C1=O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C22H18ClF2N3O4/c23-15-4-2-14(3-5-15)22(24,25)21(32)26-10-12-1-6-16-13(9-12)11-28(20(16)31)17-7-8-18(29)27-19(17)30/h1-6,9,17H,7-8,10-11H2,(H,26,32)(H,27,29,30)
|
|||||
| InChIKey |
PWBHUSLMHZLGRN-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
461.852 |
Polar area |
95.58 |
||
Complexity |
1073.521439 |
xlogp Value |
2.5092 |
|||
Heavy Count |
32 |
Rot Bonds |
5 |
|||
Hbond acc |
4 |
Hbond Donor |
2 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | 41 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | >=50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | >=50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Maximum Effect (Emax) | 51 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 54 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Maximum Effect (Emax) | 55 | % |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Cell-based Percent Inhibition (%) | 71.5 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Maximum Effect (Emax) | 88 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Maximum Effect (Emax) | >90 | % |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Maximum Effect (Emax) | >90 | % |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 107 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1530 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 29.2 | nM |
HEK293T cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | <32 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
U-266 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 62 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 824 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 9 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed |
Each Antibody-drug Conjugate Related to This Payload